Andere Sprachen Can-Fite BioPharma Ltd. Nyse

Aktien

CANF

US13471N1028

CANF

Schlusskurs Nyse Andere Börsenplätze 00:00:00 05.02.2024			% 5 Tage	% 1. Jan.
2.02 ^USD	-3.35%		-4.04%	-8.18%

01.07.	Can-Fite BioPharma Ltd. meldet Besserung bei Patient mit dekompensierter Leberzirrhose nach Behandlung mit Namodenoson	CI
28.06.	Can-Fite BioPharma Ltd. gibt positive Ergebnisse der klinischen Osteoarthritis-Studie bei Hunden bekannt, die von Vetbiolix gemeldet wurden	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson	01.07.
Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson	01.07.
Can Fite BioPharma : Other Report or Announcement	28.06.
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix	28.06.
Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix	28.06.
Can Fite BioPharma : Other Report or Announcement	26.06.
Can Fite BioPharma : Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver	24.06.
Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver	24.06.
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver	24.06.
Can Fite BioPharma : Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	10.06.
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	10.06.
Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	10.06.
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study	05.06.
Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study	05.06.
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases	29.05.
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024	27.05.
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6	23.05.
Can Fite BioPharma : Immediate Report of Meeting	22.05.
Can Fite BioPharma : NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K	22.05.
Can Fite BioPharma : Immediate Report	13.05.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Can-Fite BioPharma Ltd. Nyse

Aktien

CANF

US13471N1028

CANF

Andere Sprachen

Filter